节点文献

左旋咪唑上市后安全性再评价Ⅱ:严重不良反应文献分析

Re-evaluation of Post-marketing Safety of Levamisole(2):Literature Review of its Severe Adverse Reaction

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 杨学志郑荣远殷为勇朱振国朱英标曹立亚吴晔任经天

【Author】 Yang Xuezhi Zheng Rongyuan Yin Weiyong Zhu Zhenguo The First Affiliated Hospital of Wenzhou Medical College,Zhejiang,Wenzhou 325000,China Cao Liya Wu Ye Ren Jingtian Center for Drug Re-evaluation of SFDA

【机构】 温州医学院附属第一医院神经内科浙江省神经药物流行病学研究中心国家食品药品监督管理局药品评价中心国家食品药品监督管理局药品评价中心 (浙江温州325000)(浙江温州325000)

【摘要】 目的:了解左旋咪唑不良反应的发生情况,为临床合理用药提供参考。方法:检索1984~2005年间国内外公开发表的有关左旋咪唑上市后研究文献,进行调查登记、数据整理、统计分析。结果:共获得文献98篇,其中国内72篇,国外26篇。共报道严重不良反应638例,其中国内602例,国外36例,包括脱髓鞘脑病586例,粒细胞缺乏症6例,皮疹4例,其他不良反应42例。结论:广大用药人群和临床医生务必高度重视LMS所引起严重的不良反应,提高警惕。

【Abstract】 Objective:To provide some reasonable reference for clinical medication by investigating the adverse reaction of levamisole.Method:The literatures published between 1984 and 2005 were reviewed by re-evaluating the post- marketing levamisole and its use and then analyzed.Result:A total of 98 literatures were got,including 76 domestic litera- tures and 26 overseas literatures.638 cases with adverse drug reaction (ADR) were reported,602 cases of which were do- mestic and 36 cases were overseas.Among all the 638 cases with ADR,586 cases were ill with demyelination disease,6 cases,agranulocytosis,4 cases,erythra and 42 cases presented some other adverse reactions.Conclusion:The most medi- cation crowd and clinicians must pay high attention to the severe adverse reaction of levamisole and raise vigilance when u- sing levamisole.

【基金】 国家食品药品监督管理局药品评价中心委托与资助
  • 【文献出处】 药物流行病学杂志 ,Chinese Journal of Pharmacoepidemiology , 编辑部邮箱 ,2007年05期
  • 【分类号】R978
  • 【被引频次】14
  • 【下载频次】329
节点文献中: 

本文链接的文献网络图示:

本文的引文网络